價(jià)格 | 詢(xún)價(jià) |
包裝 | 25mg |
最小起訂量 | 25mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-11-05 |
中文名稱(chēng):CL-387785 (EGFR抑制劑) | 英文名稱(chēng):CL-387785 (EGFR抑制劑) |
有效期: 一年 | 產(chǎn)品類(lèi)別: 免疫與炎癥 Jak/Stat:IL-6 Signaling |
產(chǎn)品編號(hào) | 產(chǎn)品名稱(chēng) | 產(chǎn)品包裝 | 產(chǎn)品價(jià)格 |
SD4785-25mg | CL-387785 (EGFR抑制劑) | 25mg | 2040.00元 |
化學(xué)信息:
化學(xué)名 | N-[4-(3-bromoanilino)quinazolin-6-yl]but-2-ynamide | |
簡(jiǎn)稱(chēng) | CL-387785 | |
別名 |
EKI-785, WAY-EKI 785, CL387785, CL 387785, EKI785, WAY-EKI785, EKI 785 |
|
中文名 | N/A | |
化學(xué)式 | C18H13BrN4O | |
分子量 | 381.23 | |
CAS號(hào) | 194423-06-8 | |
純度 | 98% | |
溶劑/溶解度 |
Water<1mg/ml; DMSO14mg/ml; Ethanol<1mg/ml |
|
溶液配制 | 5mg加入1.31ml DMSO,或者每3.81mg加入1ml DMSO,配制成10mM溶液。SD4785-10mM用DMSO配制。 |
生物信息:
產(chǎn)品描述 | CL-387785 (EKI785; WAY-EKI 785) is an irreversible inhibitor of EGFR with IC50 of 370+/-120pM; is able to overcome resistance caused by the T790M mutation on a functional level. | ||||
信號(hào)通路 | JAK/STAT; Protein Tyrosine Kinase | ||||
靶點(diǎn) | EGFR | - | - | - | - |
IC50 | 370+/-120 pM | - | - | - | - |
體外研究 | CL-387785 blocked EGF-stimulated autophosphorylation of the receptor in cells (IC50 approximately 5nM), inhibited cell proliferation (IC50=31-125nM) primarily in a cytostatic manner in cell lines that overexpress EGF-R or c-erbB-2. Whereas transformation by most EGFR mutants confers on cells sensitivity to erlotinib and gefitinib, transformation by an exon 20 insertion makes cells resistant to these inhibitors but more sensitive to the irreversible inhibitor CL-387,785. CL-387,785 is able to overcome resistance caused by the T790M mutation on a functional level, correlating with effective inhibition of downstream signaling pathways. | ||||
體內(nèi)研究 | CL-387785 profoundly blocked the growth of a tumor that overexpresses EGF-R in nude mice (when given orally at 80mg/kg/day for 10 days, daily). Treatment of BPK mice with EKI-785 resulted in a marked reduction of collecting tubule (CT) cystic lesions, improved renal function, decreased biliary epithelial abnormalities, and an increased life span. Cystic animals treated with EKI-785 to postnatal day 48 (P-48) were alive and well with normal renal function, a reduced CT cystic index of 2.0 (P<0.02), a threefold increased in maximum urinary concentrating ability (P<0.01), and a significant decrease in biliary epithelial proliferation/fibrosis (P<0.01). | ||||
臨床實(shí)驗(yàn) | N/A | ||||
特征 | N/A |
相關(guān)實(shí)驗(yàn)數(shù)據(jù)(此數(shù)據(jù)來(lái)自于公開(kāi)文獻(xiàn),碧云天并不保證其有效性):
酶活性檢測(cè)實(shí)驗(yàn) | |
方法 | N/A |
細(xì)胞實(shí)驗(yàn) | |
細(xì)胞系 | N/A |
濃度 | N/A |
處理時(shí)間 | N/A |
方法 | N/A |
動(dòng)物實(shí)驗(yàn) | |
動(dòng)物模型 | N/A |
配制 | N/A |
劑量 | N/A |
給藥方式 | N/A |
產(chǎn)品編號(hào) | 產(chǎn)品名稱(chēng) | 包裝 |
SD4785-10mM | CL-387785 (EGFR抑制劑) | 10mM×0.2ml |
SD4785-5mg | CL-387785 (EGFR抑制劑) | 5mg |
SD4785-25mg | CL-387785 (EGFR抑制劑) | 25mg |
— | 說(shuō)明書(shū) | 1份 |
保存條件:
????????-20℃保存,至少一年有效。5mg和25mg包裝也可室溫保存,至少6個(gè)月有效。如果溶于非DMSO溶劑,建議分裝后-80℃保存,預(yù)計(jì)6個(gè)月內(nèi)有效。
成立日期 | 2007-07-19 (18年) | 注冊(cè)資本 | 1000.000000萬(wàn)人民幣 |
員工人數(shù) | 500人以上 | 年?duì)I業(yè)額 | ¥ 500萬(wàn)-1000萬(wàn) |
主營(yíng)行業(yè) | 生化試劑,核苷,核苷酸,寡核苷酸,抗體,蛋白組學(xué),生物活性小分子 | 經(jīng)營(yíng)模式 | 試劑 |
產(chǎn)品名稱(chēng) | 價(jià)格 | 公司名稱(chēng) | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢(xún)價(jià) |
VIP5年
|
上海澤葉生物科技有限公司
|
2024-11-18 | |
¥936.00 |
VIP13年
|
上海阿拉丁生化科技股份有限公司
|
2024-10-31 | |
¥70 |
武漢雙金精細(xì)化工有限公司
|
2024-10-16 |